Pfizer’s academic-partnered R&D unit is scrapped as part of cost-cutting measures

Pfizer’s cost cuts that began last year have stretched to the closure of a well-known internal R&D team that focused on partnering with physician-scientists to launch new medicines, including one that ultimately became the center of a $7.1 billion acquisition from Roche. 

A website for the Centers for Therapeutics Innovation (CTI) now directs to Pfizer’s more general partnering website. A spokesperson for the Big Pharma told Fierce Biotech that the company decided to close CTI’s laboratories and “embed certain CTI projects within the research units of our R&D organization.” 

The drugmaker made the decision “as part of the company’s enterprise-wide cost realignment program,” the spokesperson confirmed.

“Pfizer has many other academic collaborations that exist outside of CTI and remains committed to pursuing academic-industry collaborations designed to bridge the gap between early scientific discovery and its translation into potential new therapies,” the spokesperson said. The website was functional as recently as…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks